The difficulties inherent in distinguishing drug effects from disease occurring naturally in the community during postmarketing surveillance are emphasized. Multiple sources of confounding are possible as well as likely.
JonesColin DGLangmanMJSLawsonDHPost marketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J.1983;286: 1713–1716.
2.
JonesColin DGLangmanMJSLawsonDHReview: Post marketing surveillance of the safety of cimetidine—the problems of data interpretation. Aliment Pharmacol Ther.1987;1: 167–177.
3.
JonesColin DGLangmanMJSLawsonDHCimetidine and gastric cancer; preliminary report from post marketing surveillance study. Br Med. J.1981;285: 1311–1313.
4.
SomervilleKWFaulknerGLangmanMJS. Nonsteroidal anti inflammatory drugs and bleeding peptic ulcer. Lancet.1986;i: 462–44.
5.
WaltRKatschinskiBLoganRRising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet.1986;i: 489–492.
